Skip to main content

GRFS · Grifols SA · Metrics

Track GRFS — free
$8.15 -0.05 (-0.61%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$5.55B
Shares
680.58M
Volume · Nov 20 848.3K Avg daily vol (3M) 622.34K

GRFS metrics

61 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.15
Market cap
$5.55B

Price action

23 metrics
Price change (1W)
-6.2%
Price change (30D)
+9.4%
Price change (3M)
+1.9%
Price change (6M)
+2.1%
Price change (YTD)
-12.8%
Price change (1Y)
-3.3%
Trailing year
Price change (5Y)
-31.4%
52-week high
$9.72
52-week low
$7.02
Change from 52-week high
-16.2%
Change from 52-week low
+16.1%
Annualized volatility
31.9%
Annualized volatility (3M)
26.1%
Implied volatility (30D)
42.8%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.9
RSI (14D)
46.6
Price vs SMA 50
+4.2%
Price vs SMA 200
+2.5%
Avg volume (3M)
622,340
Relative volume
1.4
Average dollar volume
$4.88M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - General
Shares outstanding
680.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.9
reciprocal yield 111.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
1.2%
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
$0.09
Dividend growth YoY
-45.7%
Dividend growth streak
0
Last ex-dividend
2026-07-02

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-02

Profitability

9 metrics
Gross margin
38.0%
Operating margin
16.5%
Trailing 12 months
Net margin
5.3%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+4.3%
Year over year
Net income growth YoY
+156.1%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
+156.5%
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
+7.5%
Revenue CAGR (5Y)
+7.1%
EPS CAGR (3Y)
+29.8%
EPS CAGR (5Y)
-8.1%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-1.2%

Quality

14 metrics
Return on equity
7.6%
Return on assets
2.0%
Debt / equity
—
Current ratio
2.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$968.22M
Total assets
$23.13B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
167
13F filer change QoQ
0
Institutional ownership
20.5%
Conviction holders (share of 13F filers)
1.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.9%
Holder tenure
21.3
Price vs estimated holder cost
-17.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
0.9%
Latest settlement · 8.1 days to cover
Days to cover
8.1d
Short-squeeze score
47 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1438569 CUSIP 398438408 13F (30d) 181 filings 153 filers Visit website Investor relations